CV-MG02
Myasthenia Gravis (MG)
Phase 2Active
Key Facts
About Curavac
CuraVac is a private, clinical-stage biotech focused on creating potentially curative immunotherapies for autoimmune diseases. Its core platform utilizes complementary peptides to retrain the immune system, aiming for long-term remission. The company is advancing its lead candidate, CV-MG02, towards a Phase 2 trial for Myasthenia Gravis, with a pipeline targeting other major autoimmune conditions like Multiple Sclerosis and Type 1 Diabetes. CuraVac operates with a lean, network-based team and holds Orphan Drug Designation for its lead program in both the US and EU.
View full company profileTherapeutic Areas
Other Myasthenia Gravis (MG) Drugs
| Drug | Company | Phase |
|---|---|---|
| CNP Program | COUR Pharmaceuticals | Unknown |
| Batoclimab | Immunovant | Phase 3 |
| IMVT-1402 | Immunovant | Phase 2 |
| Orelabrutinib | Zenas BioPharma | Phase 3 |
| Telitacicept | Vor Biopharma | Marketed |